2011•China Practical MedicineRequires access

THe clinical observation of different doses of atorvastatin treatment of type 2 diabetes and dyslipidemia

Li Su

Open publisher page 0 citations

Abstract

Objective To observe the different doses of Atorvastatin in type 2 diabetic dyslipidemia in patients with clinical efficacy.Methods 97 cases of type 2 diabetes and dyslipidemia were randomly divided into A group of 31 cases of B-group of 34 patients in group C 32 patients,while in the conventional hypoglycemic night oral tablets atorvastatin group A 10 mg,B group 20 mg,C group 40 mg,After 8 weeks,the patient TC,TG,HDL-C,LDL-C,hs-CRP changes were analyzed.Results After 8 weeks,group B,group C,TC,TG,LDL-C levels were significantly lower than in group A (P0.05),B Group Group C HDL-C than in group A increased significantly (P0.05),hs-CRP level than the A group B group C was significantly decreased (P0.01).Group B and C no significant difference between groups,but group C compared with Group A Group B side-effects.Conclusion 20 mg atorvastatin tablets can not only improve dyslipidemia in type 2 diabetic patients with blood lipids,can also reduce plasma hs-CRP levels,has anti-inflammatory role of plaque stability.

About this research paper

What this paper is about

Objective To observe the different doses of Atorvastatin in type 2 diabetic dyslipidemia in patients with clinical efficacy.Methods 97 cases of type 2 diabetes and dyslipidemia were randomly divided into A group of 31 cases of B-group of 34 patients in group C 32 patients,while in the conventional hypoglycemic night oral tablets atorvastatin group A 10 mg,B group 20 mg,C group 40 mg,After 8 weeks,the patient TC,TG,HDL-C,LDL-C,hs-CRP changes were analyzed.Results After 8 weeks,group B,group C,TC,TG,LDL-C levels were significantly lower than in group A (P0.05),B Group Group C HDL-C than in group A increased significantly (P0.05),hs-CRP level than the A group B group C was significantly decreased (P0.01).Group B and C no significant difference between groups,but group C compared with Group A Group B side-effects.Conclusion 20 mg atorvastatin tablets can not only improve dyslipidemia in type 2 diabetic patients with blood lipids,can also reduce plasma hs-CRP levels,has anti-inflammatory role of plaque stability.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To observe the different doses of Atorvastatin in type 2 diabetic dyslipidemia in patients with clinical efficacy.Methods 97 cases of type 2 diabetes and dyslipidemia were randomly divided into A group of 31 cases of B-group of 34 patients in group C 32 patients,while in the conventional hypoglycemic night oral tablets atorvastatin group A 10 mg,B group 20 mg,C group 40 mg,After 8 weeks,the patient TC,TG,HDL-C,LDL-C,hs-CRP changes were analyzed.Results After 8 weeks,group B,group C,TC,TG,LDL-C levels were significantly lower than in group A (P0.05),B Group Group C HDL-C than in group A increased significantly (P0.05),hs-CRP level than the A group B group C was significantly decreased (P0.01).Group B and C no significant difference between groups,but group C compared with Group A Group B side-effects.Conclusion 20 mg atorvastatin tablets can not only improve dyslipidemia in type 2 diabetic patients with blood lipids,can also reduce plasma hs-CRP levels,has anti-inflammatory role of plaque stability.

Key concepts: Dyslipidemia, Medicine, Atorvastatin, Group B, Group A, Internal medicine, Type 2 diabetes, Gastroenterology

Related papers

Back to paper searchBrowse research topicsOriginal source
THe clinical observation of different doses of atorvastatin treatment of type 2 diabetes and dyslipidemia — Research Paper | ScholarLens